---
title: "Verzenio (abemaciclib), all indications: Safety questions"
description: "Safety questions on Verzenio (abemaciclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Safety management, Warnings, and Monitoring. Questions: Was Verzenio carcinogenic or mutagenic in animal and laboratory studies? Does Verzenio prolong the QT interval? How should diarrhea from Verzenio be managed? How should patients prepare for Verzenio diarrhea before starting treatment? 7 further questions follow. 11 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/verzenio/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib), all indications: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)  
Indication pages: [HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)

## Safety

<a id="verzenio-carcinogenicity"></a>

### Was Verzenio carcinogenic or mutagenic in animal and laboratory studies?

> “Abemaciclib was assessed for carcinogenicity in a 2-year rat study. Abemaciclib was not carcinogenic in male and female rats at oral doses up to 3 mg/kg/day (approximately 1 time the exposure at the maximum recommended human dose based on AUC).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Abemaciclib%20was%20assessed%20for%20carcinogenicity,human%20dose%20based%20on%20AUC%29.)

> “Abemaciclib and its active human metabolites M2 and M20 were not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or human peripheral blood lymphocytes. Abemaciclib, M2, and M20 were not clastogenic in an in vivo rat bone marrow micronucleus assay.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Abemaciclib%20and%20its%20active%20human,rat%20bone%20marrow%20micronucleus%20assay.)

<a id="verzenio-qt-interval"></a>

### Does Verzenio prolong the QT interval?

> “Based on evaluation of the QTc interval in patients and in a healthy volunteer study, abemaciclib did not cause large mean increases (i.e., 20 ms) in the QTc interval.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Based%20on%20evaluation%20of%20the,ms%29%20in%20the%20QTc%20interval.)

## Safety management

<a id="verzenio-diarrhea-management"></a>

### How should diarrhea from Verzenio be managed?

> “Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up [see Patient Counseling Information (17)]. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold VERZENIO until resolution to ≤Grade 1, and then resume VERZENIO at the next lower dose [see Dosage and Administration (2.2)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Instruct%20patients%20to%20start%20antidiarrheal,%5Bsee%20Dosage%20and%20Administration%20%282.2%29%5D.)

> “Table 3: VERZENIO Dosage Modifications and Management — Diarrhea
> At the first sign of loose stools, start treatment with antidiarrheal agents and increase intake of oral fluids.
> CTCAE Grade	VERZENIO Dosage Modifications
> Grade 1	No dosage modification is required.
> Grade 2	If toxicity does not resolve within 24 hours to ≤Grade 1, Withhold until resolution. No dosage reduction is required.
> Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures	Withhold until toxicity resolves to ≤Grade 1.
> Resume at next lower dose.
> Grade 3 or 4 or requires hospitalization	Withhold until toxicity resolves to ≤Grade 1.
> Resume at next lower dose.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%203%3A%20VERZENIO%20Dosage%20Modifications,Resume%20at%20next%20lower%20dose.)

> “Early identification and intervention is critical for the optimal management of diarrhea. Instruct patients that at the first sign of loose stools, they should start antidiarrheal therapy (for example, loperamide) and notify their healthcare provider for further instructions and appropriate follow up.
> Encourage patients to increase oral fluids.
> If diarrhea does not resolve with antidiarrheal therapy within 24 hours to ≤Grade 1, suspend VERZENIO dosing [see Dosage and Administration (2.2)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Early%20identification%20and%20intervention%20is,%5Bsee%20Dosage%20and%20Administration%20%282.2%29%5D.)

> “Once an antidiarrheal agent is started, advise patients to follow up if symptoms do not improve after the first 24 hours.”

Source: [VERZENIO: Dose Modifications | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing-modifications#:~:text=Once%20an%20antidiarrheal%20agent%20is,after%20the%20first%2024%20hours.)

Note: The last passage is from the dose modifications page of the Verzenio HCP site.

<a id="verzenio-diarrhea-plan"></a>

### How should patients prepare for Verzenio diarrhea before starting treatment?

> “• Before starting Verzenio, ensure your patients have an over-the-counter 
> antidiarrheal medicine available 
> • At the first sign of loose stools, inform patients to start the antidiarrheal 
> medicine and notify their healthcare team 
> • Discuss any dietary changes with the healthcare team prior  
> to initiating treatment”

Source: [VERZENIO: Diarrhea Monitoring and Management Guide, page 3, captured 2026-11-14](https://verzenio.lilly.com/assets/pdf/diarrhea_guide.pdf#page=3)

Note: This passage is from the Diarrhea Monitoring and Management Guide that the resources page of the Verzenio HCP site links.

<a id="verzenio-diarrhea-diet"></a>

### Verzenio diarrhea: what foods should patients avoid?

> “Diet may impact your 
> patients’ experience  
> with diarrhea<sup>5,6</sup>”

Source: [VERZENIO: Diarrhea Monitoring and Management Guide, page 3, captured 2026-11-14](https://verzenio.lilly.com/assets/pdf/diarrhea_guide.pdf#page=3)

> “• Advise your patients to continue eating their normal diet with 
> modifications as needed 
> • These suggestions serve as a guide and are not specific to Verzenio”

Source: [VERZENIO: Diarrhea Monitoring and Management Guide, page 3, captured 2026-11-14](https://verzenio.lilly.com/assets/pdf/diarrhea_guide.pdf#page=3)

> “WHAT YOUR PATIENTS 
> SHOULD AVOID
> • Dairy or high-fiber products
> • Fatty, greasy, or spicy foods 
> • Caffeinated or alcoholic 
> beverages”

Source: [VERZENIO: Diarrhea Monitoring and Management Guide, page 3, captured 2026-11-14](https://verzenio.lilly.com/assets/pdf/diarrhea_guide.pdf#page=3)

Note: This passage is from the Diarrhea Monitoring and Management Guide that the resources page of the Verzenio HCP site links.

<a id="verzenio-neutropenia-dose"></a>

### How is the Verzenio dose adjusted for neutropenia?

> “Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.
> CTCAE Grade	VERZENIO Dosage Modifications
> Grade 1 or 2	No dosage modification is required.
> Grade 3	Withhold until toxicity resolves to ≤Grade 2.
> Dosage reduction is not required.
> Grade 3 recurrent, or Grade 4	Withhold until toxicity resolves to ≤Grade 2.
> Resume at next lower dose.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=current%20treatment%20guidelines.-,Monitor%20complete%20blood%20counts%20prior%20to%20the%20start%20of%20VERZENIO,Resume%20at%20next%20lower%20dose.)

> “a If blood cell growth factors are required, withhold VERZENIO dosage for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2. Resume at next lower dose unless already performed for the toxicity that led to the use of the growth factor. Growth factor use as per current treatment guidelines.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=a%20If%20blood%20cell%20growth,as%20per%20current%20treatment%20guidelines.)

## Warnings

<a id="verzenio-neutropenia"></a>

### Does Verzenio cause low white blood cell counts (neutropenia)?

> “Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Neutropenia%2C%20including%20febrile%20neutropenia%20and,in%20patients%20treated%20with%20VERZENIO.)

> “Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving VERZENIO. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days [see Adverse Reactions (6.1)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Across%20five%20clinical%20trials%20in%203899%20patients%2C%20neutropenia,days%20%5Bsee%20Adverse%20Reactions%20%286.1%29%5D.)

> “Febrile neutropenia has been reported in <1% of patients receiving VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Febrile%20neutropenia%20has%20been%20reported,were%20observed%20in%20MONARCH%202.)

> “Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia [see Dosage and Administration (2.2)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Counseling%20Information%20%2817%29%5D.-,Monitor%20complete%20blood%20counts%20prior%20to%20the%20start%20of%20VERZENIO,%5Bsee%20Dosage%20and%20Administration%20%282.2%29%5D.)

> “Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%209%3A%20Laboratory%20Abnormalities%20%28%E2%89%A510%25%29,Arms%20of%20%E2%89%A52%25%5D%20in%20monarchE)

> “Neutrophils decreased	84	18	0.7	23	1.6	0.3”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Neutrophils%20decreased,0.3)

Note: Section 5.7 of the Prescribing Information names the five trials as monarchE, MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3. Section 5.3 of the Prescribing Information describes MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3 as trials in advanced or metastatic breast cancer. In the Table 9 row, columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2791: all grades, Grade 3, Grade 4) followed by tamoxifen or an aromatase inhibitor alone (N=2800: all grades, Grade 3, Grade 4), in percent.

<a id="verzenio-liver"></a>

### Can Verzenio cause liver problems?

> “Grade ≥3 ALT (2% to 6%) and AST (2% to 3%) were reported in patients receiving VERZENIO.
>
> Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Grade%20%E2%89%A53%20ALT%20%282%25%20to,from%2011%20to%2015%20days.)

> “Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation [see Dosage and Administration (2.2)].”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Monitor%20liver%20function%20tests%20%28LFTs%29,%5Bsee%20Dosage%20and%20Administration%20%282.2%29%5D.)

> “Table 4: VERZENIO Dosage Modifications and Management — Hepatotoxicity
>
> Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal.
>
>
> Monitor ALT, AST, and serum bilirubin prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.
> CTCAE Grade for ALT and AST	VERZENIO Dosage Modifications
> Grade 1 (>ULN-3.0 x ULN)
> Grade 2 (>3.0-5.0 x ULN),
> WITHOUT increase in total bilirubin above 2 x ULN	No dosage modification is required.
> Persistent or Recurrent Grade 2, or Grade 3 (>5.0-20.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN	Withhold until toxicity resolves to baseline or Grade 1.
> Resume at next lower dose.
> Elevation in AST and/or ALT >3 x ULN WITH total bilirubin >2 x ULN, in the absence of cholestasis	Discontinue VERZENIO.
> Grade 4 (>20.0 x ULN)	Discontinue VERZENIO.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%204%3A%20VERZENIO%20Dosage%20Modifications,Discontinue%20VERZENIO.)

> “Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%209%3A%20Laboratory%20Abnormalities%20%28%E2%89%A510%25%29,Arms%20of%20%E2%89%A52%25%5D%20in%20monarchE)

> “ALT increased	37	2.5	<0.1	24	1.2	0
> AST increased	31	1.5	<0.1	18	0.9	0”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=ALT%20increased,0)

Note: Section 5.3 of the Prescribing Information describes MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3 as trials in advanced or metastatic breast cancer. The last passage gives the monarchE rows of Table 9. Columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2791: all grades, Grade 3, Grade 4) followed by tamoxifen or an aromatase inhibitor alone (N=2800: all grades, Grade 3, Grade 4), in percent.

<a id="verzenio-creatinine-kidney"></a>

### Does Verzenio affect kidney function or raise serum creatinine?

> “VERZENIO can increase serum creatinine. Across five clinical trials in 3899 patients (monarchE, MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3), increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO treatment, remained elevated through the treatment, and were reversible upon treatment discontinuation. These increases were not associated with changes in glomerular function [see Adverse Reactions (6.1)]. The increases in serum creatinine may be due to inhibition of renal tubular secretion transporters [see Clinical Pharmacology (12.3)]. During VERZENIO treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=VERZENIO%20can%20increase%20serum%20creatinine.,cystatin%20C%2C%20or%20calculated%20GFR.)

Note: Section 5.3 of the Prescribing Information describes MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3 as trials in advanced or metastatic breast cancer.

<a id="verzenio-contraindications"></a>

### What are the contraindications for Verzenio?

> “None.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=4%20CONTRAINDICATIONS-,None.)

Note: Section 4 (Contraindications) of the Verzenio Prescribing Information reads "None."

## Monitoring

<a id="verzenio-monitoring"></a>

### What monitoring does Verzenio require before and during treatment?

> “Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Counseling%20Information%20%2817%29%5D.-,Monitor%20complete%20blood%20counts%20prior%20to%20the%20start%20of%20VERZENIO,months%2C%20and%20as%20clinically%20indicated.)

> “Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Monitor%20liver%20function%20tests%20%28LFTs%29,months%2C%20and%20as%20clinically%20indicated.)

> “Verify pregnancy status in females of reproductive potential prior to initiating treatment with VERZENIO.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Verify%20pregnancy%20status%20in%20females,to%20initiating%20treatment%20with%20VERZENIO.)

> “During VERZENIO treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=During%20VERZENIO%20treatment%2C%20use%20alternative,cystatin%20C%2C%20or%20calculated%20GFR.)

## Related pages
- [Medical information: Verzenio (abemaciclib): All indications](https://www.evicenter.com/medical-information/verzenio)
- [Indication](https://www.evicenter.com/medical-information/verzenio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/verzenio/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/verzenio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/verzenio/access-and-coverage)
